Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OROS Hydromorphone vs Morphine for Cancer Pain
NCT00410540Phase 3
Key facts
- Status
- Completed
- Sponsor
- ALZA Corporation
- Modality
- Orthosteric Ligands
- Drugs
- hydromorphone
- Conditions
- cancer pain
01
Overview
Phase 3, randomised, double-blind trial of hydromorphone in cancer pain (2 arms), sponsored by ALZA Corporation. Primary endpoint: Brief Pain Inventory Worst Pain in the Past 24 Hours. Status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Hydromorphone Arm
Hydromorphone IR followed by OROS hydromorphone SR.
Morphine Arm
Morphine IR followed by Morphine SR.
03
Endpoints
Primary
Brief Pain Inventory Worst Pain in the Past 24 Hours
Secondary
Other pain measures
Various questionnaires
Safety and tolerability
Beyond the preview
Go deeper on NCT00410540.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410540.